Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04014374 · ClinicalTrials.gov registry record
Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
A clinical trial of Cutaneous T Cell Lymphoma and Leukemia/Lymphoma, sponsored by Kyowa Kirin.
- Recruiting
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT04014374: Recruiting study of Cutaneous T Cell Lymphoma and Leukemia/Lymphoma, sponsored by Kyowa Kirin.
NCT04014374 is a study of Cutaneous T Cell Lymphoma and Leukemia/Lymphoma that is actively recruiting participants, run by Kyowa Kirin. The registered enrollment target is 150 participants, above the 61-participant average among 23 other Cutaneous T Cell Lymphoma trials with a reported enrollment target (146% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04014374, a study of Cutaneous T Cell Lymphoma and Leukemia/Lymphoma, is actively recruiting participants, sponsored by Kyowa Kirin.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a non-interventional cohort study evaluating non-relapse mortality and toxicities in patients with CTCL or ATLL treated with mogamulizumab pre- or post- alloHCT for patients transplanted beginning January 1, 2012 until accrual is complete.
Primary Outcome
This study will utilize comprehensive report form (CRF) data, modified transplant essential data (TED) and supplemental data. In patients with only TED data the supplemental data will provide the required additional information for data analyses to meet the objectives of the study.
Conditions Studied
Study Locations (1)
Wisconsin
- CIBMTR - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2019-09-10 |
| Est. Completion | 2030-02 |
What NCT04014374 shows while recruiting
NCT04014374 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 61-participant average among 23 other Cutaneous T Cell Lymphoma trials with a reported enrollment target (146% higher).
The record links to 3 conditions, with Cutaneous T Cell Lymphoma appearing as the primary indexed condition, and to 0 interventions.
NCT04014374 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04014374 about?
NCT04014374 is a clinical study titled "Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab". This is a non-interventional cohort study evaluating non-relapse mortality and toxicities in patients with CTCL or ATLL treated with mogamulizumab pre- or post- alloHCT for patients transplanted beginning January 1, 2012 until accrual is complete.
What is the current status of trial NCT04014374?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2019-09-10. Estimated completion is 2030-02.
What conditions does trial NCT04014374 study?
This clinical trial studies the following conditions: Cutaneous T Cell Lymphoma, Leukemia/Lymphoma, ATLL.
Who is sponsoring clinical trial NCT04014374?
This trial is sponsored by Kyowa Kirin, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04014374 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous T Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04014374's enrollment target sits among peer trials
150 3rd of 23 higher than 21 of 23 other Cutaneous T Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cutaneous T Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Photopheresis in Early-stage Mycosis Fungoides
RECRUITING · Phase 2
-
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
RECRUITING · NA
-
Characterization of the Microbiome in Cutaneous T Cell Lymphoma
RECRUITING
-
Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
RECRUITING · Phase 1
-
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
RECRUITING · Phase 1
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI